TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02402127

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear
Study: NCT06426966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre
Description: Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity.
Study: NCT03975400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: search engine advertisement campaign
Description: This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
Study: NCT03454256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Rehabilitation System
Study: NCT02542943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 1
Description: (1.5% w/w KOX, pH 4.5)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 2
Description: (1.5% w/w KOX, pH 7)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse
Description: (0% w/w KOX, pH 4.5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard fluoride toothpaste
Description: 1000ppm fluoride as sodium monofluorophosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard fluoride toothpaste
Description: 1000ppm fluoride as sodium monofluorophosphate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard fluoride toothpaste
Description: 1000ppm fluoride as sodium monofluorophosphate
Study: NCT03725020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride varnish
Description: The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
Study: NCT02118922

Intervention type: PROCEDURE
Intervention: Brillouin imaging

Intervention type: PROCEDURE
Intervention: Brillouin imaging

Intervention type: PROCEDURE
Intervention: Brillouin imaging

Intervention type: PROCEDURE
Intervention: Brillouin imaging

Intervention type: PROCEDURE
Intervention: Brillouin imaging

Intervention type: PROCEDURE
Intervention: Brillouin imaging

Intervention type: PROCEDURE
Intervention: Brillouin imaging
Study: NCT03570970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: Banapenem to be used anti-infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: Banapenem to be used anti-infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: Banapenem to be used anti-infection
Study: NCT01202513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% topical ophthalmic solution
Study: NCT03609359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Study: NCT00925366

Intervention type: OTHER
Group type: OTHER
Intervention: Imaging Procedure
Description: CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
Study: NCT02823028

Intervention type: DRUG
Group type: OTHER
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
Study: NCT01824810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myoActivation
Description: In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural Prolotherapy
Description: Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Needling Control
Description: The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
Study: NCT02353819

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
Study: NCT03551405

Intervention type: RADIATION
Intervention: CBCT scan
Description: CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
Study: NCT03465397

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biomarkers driven immunosuppressive therapy
Description: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
Study: NCT01833728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nefopam-propacetamol combination
Description: Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propacetamol alone
Description: In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
Study: NCT02548481

Intervention type: OTHER
Intervention: BESTA scale
Description: BESTA scale is administrated at T0, T1 and T2.
Study: NCT02512523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study: NCT02249949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efatutazone
Description: Given PO
Study: NCT03653507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab were administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin were administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin were administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capecitabine
Description: Capecitabine were administered orally twice daily (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine were administered orally twice daily (bid).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo were administered as a minimum 2-hour IV infusion.
Study: NCT03866382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT00464061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volinanserin
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT03866382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT02994472

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gastric emptying scintigraphy using 99mTc-DTPA
Study: NCT01217879

Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT03888040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
Study: NCT04717648

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical test
Description: C Reactive protein and sodium

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical test
Description: C Reactive protein and sodium
Study: NCT03982719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief protocol
Description: This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intense protocol
Description: This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
Study: NCT01267110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI2 intervention arm
Description: For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
Study: NCT02131103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct.
Study: NCT02042586

Intervention type: OTHER
Intervention: Analysis of movement before total hip replacement

Intervention type: OTHER
Intervention: Analysis of movement before total hip replacement

Intervention type: OTHER
Intervention: Analysis of movement after total hip replacement
Study: NCT00160017

Intervention type: BEHAVIORAL
Intervention: Breakthrough collaborative
Description: Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
Study: NCT03619096

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunnel technique for Root coverage with Porcine collagen Matrix
Description: Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: extended fla technique for Root coverage with Porcine collagen Matrix
Description: Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
Study: NCT03655301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Single dose of 1000 mg is administered orally.
Study: NCT02056886

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLN detection +/- complementary axillary lymphadenectomy
Description: breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN detection +/- complementary axillary lymphadenectomy
Description: breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLN detection +/- complementary axillary lymphadenectomy
Description: breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
Study: NCT01226641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: CPAP treatment with telemedicine system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care, including CPAP
Study: NCT03393819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuraPrep
Description: DuraPrep surgical solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep
Description: ChloraPrep surgical solution